Eurofins Scientific shares closed the Tuesday session on January 20 at 70.36 euros, down 2.17% from the previous day's close of 71.92 euros. This correction follows an outstanding twelve-month performance, with the share price having increased by 49.48%. However, the value of the analysis laboratory specialist remains well-oriented over three months with a gain of 12.54%. Technically, the RSI shows a level of 85, indicating an overbought zone that could justify this pause. Nevertheless, the price continues to move above its 50-day (61.71 euros) and 200-day (60.86 euros) moving averages, confirming the strength of the underlying bullish trend. The proximity of the resistance threshold at 73.12 euros poses a short-term obstacle for the continuation of the movement.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The group continued its share buyback program with the acquisition of 30,000 shares between January 12 and 16 at an average price of 71.91 euros, after having bought back 70,000 shares at the beginning of January for 4.7 million euros. This strategy reflects the management's confidence in the stock's prospects. On the analyst side, Kepler Cheuvreux raised its price target to 81 euros from 72 euros previously on January 13, while Morgan Stanley raised it to 64 euros at the beginning of January. These recommendations suggest a potential upside of 15.16% for the highest target compared to the current price. Bernstein, meanwhile, maintains an outperformance recommendation with a target of 72.30 euros.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.